Takeda has launched a new endowment scheme through which it will contribute a total of around $11 million to various Global Fund projects in Africa.
Takeda has launched a new endowment scheme through which it will contribute a total of around $11 million to various Global Fund projects in Africa.
The Japanese firm concedes that its contributions to health initiatives in developing countries have been low, but said the move...
Multi-blockbuster falls short in a giant cell arteritis study.
4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
